Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

OBJECTIVE: The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. METHODS: Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Keystone, E C, Genovese, M C, Klareskog, L, Hsia, E C, Hall, S T, Miranda, P C, Pazdur, J, Bae, S-C, Palmer, W, Zrubek, J, Wiekowski, M, Visvanathan, S, Wu, Z, Rahman, M U
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674549/
https://www.ncbi.nlm.nih.gov/pubmed/19066176
http://dx.doi.org/10.1136/ard.2008.099010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674549/
https://www.ncbi.nlm.nih.gov/pubmed/19066176
http://dx.doi.org/10.1136/ard.2008.099010

Ejemplares similares